MiMedx stock: FTC requests more merger documents. Why it matters for MiMedx stock?

Published on 10/23/2026 at 03:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MiMedx received the request on October 15, 2026, extending review by 30 days. MiMedx stock has results due October 28, 2026.

Merger review and reporting date

MiMedx received an FTC Second Request on October 15, 2026, extending the waiting period by 30 days after substantial compliance.
Second-quarter 2026 revenue reached USD 64.36 million against USD 63.46 million in consensus estimates.
MiMedx stock last stood at USD 3.93 on Nasdaq on October 22, 2026.
MiMedx scheduled its third-quarter 2026 results for October 28, 2026.

MDXG, US6024961012, Illustration mit AI erstellt.

MiMedx Group (ISIN US6024961012) received a Federal Trade Commission Second Request on October 15, 2026, extending the waiting period for its proposed Sanara MedTech merger by 30 days after substantial compliance. The regulatory step arrives before the company reports third-quarter results on October 28, 2026.

Merger review adds a timing hurdle

According to StockTitan, MiMedx and Sanara each received requests for additional information and documents from the FTC on October 15, 2026. The request extends the Hart-Scott-Rodino waiting period until 30 days after the companies substantially comply, unless the parties extend the period voluntarily or the FTC ends it earlier.

What does the 30-day review mean?

The transaction remains subject to the end or termination of the waiting period and other closing conditions, so the regulatory process now sits between the merger agreement and completion. For MiMedx, the timing matters because the proposed acquisition is intended to expand its surgical portfolio while adding another execution milestone before closing.

Three dated events shape the story

On July 29, 2026, MiMedx reported second-quarter revenue of USD 64.36 million, versus USD 63.46 million in consensus estimates, a 1.42 percent difference, according to MarketBeat. On October 6, 2026, seven analysts supported a Moderate Buy consensus and an average USD 8.57 target, as reported by MarketBeat. The October 15, 2026 FTC request is the latest event.

October 28 brings the next test

MiMedx scheduled its third-quarter 2026 operating and financial results for October 28, 2026, after the market close, with the conference call set for 4:30 p.m. ET. The release covers the quarter ended September 30, 2026, placing operating performance alongside the unresolved merger timetable.

Stock context remains event driven

The last Nasdaq price was USD 3.93 on October 22, 2026 at 4:00 p.m. ET. MiMedx had a market capitalization of USD 572.8 million on October 22, 2026, while its 52-week range was USD 3.03 to USD 7.97. The next hard date is the October 28 results release, while the FTC review supplies the central transaction risk.